Research for Resistance Factors in the Treatment of Lymphoid Hemopathy

NCT07385612 | Not Yet Recruiting

• 1 other identifier: RC14_0358
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 4

Brief Summary

In order to promote translational research on the molecular pathways involved in resistance to treatments for mantle cell lymphoma (MCL), the clinical haematology department of the University Hospital Center (CHU) of Nantes has established, since 2016, the REFRACT-LyMa (Research on Factors of Resistance to Chemotherapies and Innovative Therapies in Mantle Cell Lymphoma) cohort-biocollection of blood and bone marrow samples from patients with MCL. Thanks to the close collaborations with team 11 of the Integrated Cancer Research and Immunology Center Nantes Angers (CRCI²NA), which specializes in studying the molecular pathways involved in resistance to treatments for hematological cancers, we wish to broaden the scope of research to other B-cell non-Hodgkin lymphomas (B-NHL). That is why today the REFRACT-LyMa cohort-biocollection aims to expand to malignant hematopathies involving mature B cells (Research on Factors of Resistance to Chemotherapies and Innovative Therapies in Mature B-Cell Lymphoid Hemopathies).

Conditions

MATURE B-CELL LYMPHOIDS

Keywords

B-cell non-Hodgkin lymphoma; treatments resistance; tumor microenvironment; biocollection

Outcome Measures

Primary Outcomes (1)

• Characterization of the tumor

  Characterization of the tumor and its microenvironment in B-NHL in order to develop preclinical models of ex vivo culture and genetic modifications of primary B-NHL cells.

  10 years

Secondary Outcomes (3)

• Preclinical model

  10 years

• Preclinical model

  10 years

• Data analysis

  10 years

Study Arms (1)

Newly diagnosed or relapsed NHL-B patients (based on ongoing translational research studies)

Clinical data collection and blood, bone marrow, lymphadenopathy as well as pleural fluid and ascites sampling at the time of inclusion (for diagnosis or relapse) and at each relapse/progression.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Newly diagnosed or relapsed B-NHL patients managed in the hematology departments of Nantes, La Roche-Sur-Yon, Saint-Nazaire and Poitiers.

You may qualify if:

• Patient affected by B-NHL (at diagnosis or relapse).
• Patient who has signed the consent form.
• Patient affiliated with a social security system.

You may not qualify if:

• Minor patients.
• Adults under guardianship.
• Protected persons.

Sponsors & Collaborators

• Nantes University Hospital: lead

Study Sites (4)

CHD Vendée

La Roche-sur-Yon, France

Location

CHU Nantes

Nantes, France

Location

CHU de Poitiers

Poitiers, France

Location

CH de Saint-Nazaire

Saint-Nazaire, France

Location

MeSH Terms

Conditions

Lymphoma, B-Cell

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Benoit TESSOULIN, MD

CONTACT

+33 2 40 08 32 71; benoit.tessoulin@chu-nantes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 21, 2026
• First Posted: February 4, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2036
• Study Completion (Estimated): June 1, 2036
• Last Updated: June 12, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (4)